Vesilute Research
Vesilute is a trade name for the dipeptide Glu-Asp. The one indexed animal study found no difference from its amino acids on the three endpoints it measured.
Shop by category
Growth Hormone Axis ResearchRegeneration ResearchPeptide BioregulatorsCognitive & Neuropeptide ResearchMetabolic & Cellular ResearchMelanocortin & Endocrine ResearchDermal Peptide ResearchImmune & Thymic ResearchN-Acetyl-Epitalon is an N-acetylated form of epitalon. Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly, written AEDG [1]. This page sets out what has been published about N-Acetyl-Epitalon. The honest answer is almost nothing, and the reason that matters is set out below.
PubMed searches run on 27 August 2026 returned zero records under every name variant tried. The variants included n-acetyl-epitalon, n-acetyl epitalon, N-acetyl epithalon, acetyl epitalon, acetylated epitalon, Ac-AEDG, epitalon amidate and N-acetyl-Ala-Glu-Asp-Gly [2].
The zero is not a search artifact. The parent compound returns 132 records on the same index on the same day [2]. The name is simply absent.
There is no in vitro study, no animal study, no human study and no review of this compound. A null PubMed search shows absence from PubMed, not absence from all peer review. Unindexed or non-English work may exist. None could be located.
PubChem holds one record, CID 171390141, titled N-Acetyl Epitalon, formula C16H24N4O10, molecular weight 432.38, UNII UXR7AF6R4F [3]. It carries no CAS number, and its full synonym list runs to three items [3].
That record describes the N-acetylated free acid. Material sold under this name is commonly described instead as an amidate, meaning a C-terminal amide. Those are two different molecules. No public structure record for the amidate could be found, so the name alone does not settle which one is in a given vial.
This is the one genuinely informative point available.
Acetylating the N-terminus removes the free alpha-amino group. In the family's flagship in silico modeling paper, dipeptides were screened as two separate sets of 400, one with free termini and one with blocked termini [4]. Blocking a terminus was handled as a change to the modeled DNA interaction, not as a cosmetic edit.
So even taking the proposed DNA-binding mechanism entirely at face value, results reported for epitalon cannot be assumed to hold for the acetylated form. Whether they do has never been tested.
This paragraph is background on the group, not evidence for this compound.
Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology hold patents covering these peptides [5]. They developed the compounds and publish on them under their own registered trademarks [6]. Khavinson is an author on 493 PubMed records [7]. He is a co-inventor, one of four, on a granted epitalon patent [5]. That patent is assigned to his own institute's clinic company. A 2020 paper from the group declares no patent or licensing arrangement [8].
Epitalon was originally derived from Epithalamin, a crude bovine pineal extract [6]. When the FDA reviewed the 26 articles submitted as evidence for epitalon, none discussed epitalon and seven discussed Epithalamin instead [9]. Those are different substances. None of that data is data on this compound.
Nothing here describes a use in people.
No. There is no human study of this compound, and no animal or in vitro study either. PubMed returned zero records under every name variant tried on 27 August 2026. That search establishes absence from PubMed rather than absence from all peer review.
It cannot be assumed to. Acetylation removes the free alpha-amino group at the N-terminus. The family's flagship in silico paper screened free-terminus and blocked-terminus dipeptides as two separate sets rather than as equivalents. No study has tested whether epitalon's reported effects survive the modification.
References
Vesilute is a trade name for the dipeptide Glu-Asp. The one indexed animal study found no difference from its amino acids on the three endpoints it measured.
An evidence-led look at Vilon research: how independent the literature is, animal findings including an adverse one, and a computational DNA mechanism.
An evidence-led look at Vesugen research: identity and naming, its presence inside four other products, and two uncontrolled human reports.
An evidence-led look at Thymalin research: what the preparation actually is, the COVID-19 trial, the older human literature, and what is unproven.
An evidence-led look at Testagen research: what the compound is, the entire published literature, and the questions that remain unstudied.
An evidence-led look at Prostamax research: a safety signal in its clearest result, identity as a defined peptide not an extract, and what is untested.